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Abstract: Dynamic structural transitions within the seven-
transmembrane bundle represent the mechanism by which G-
protein-coupled receptors convert an extracellular chemical
signal into an intracellular biological function. Here, the
conformational dynamics of the neuropeptide Y receptor type
2 (Y2R) during activation was investigated. The apo, full
agonist-, and arrestin-bound states of Y2R were prepared by
cell-free expression, functional refolding, and reconstitution
into lipid membranes. To study conformational transitions
between these states, all six tryptophans of Y2R were 13C-
labeled. NMR-signal assignment was achieved by dynamic-
nuclear-polarization enhancement and the individual func-
tional states of the receptor were characterized by monitoring
13C NMR chemical shifts. Activation of Y2R is mediated by
molecular switches involving the toggle switch residue
Trp2816.48 of the highly conserved SWLP motif and
Trp3277.55 adjacent to the NPxxY motif. Furthermore, a con-
formationally preserved “cysteine lock”-Trp11623.50 was iden-
tified.
Introduction
G protein-coupled receptors (GPCRs) are ubiquitously
found in humans and represent important pharmacological
targets.[1] Conformational flexibility represents a hallmark of
GPCR function while their characteristic structural motif is
the seven-transmembrane (TM) helix bundle. Binding of an
extracellular ligand induces a cascade of dynamic structural
rearrangements within the TM region, especially a character-
istic outwards movement of TM6,[2] representing the initial
signal transduction events. For the molecular understanding
of the biological function of GPCRs, detailed characterization
of the conformational transitions during activation is essen-
tial. As of today, structural data of 67 GPCRs (https://
zhanglab.ccmb.med.umich.edu/GPCR-EXP/) determined in
the inactive, intermediate or active conformations are avail-
able. While the structural basis for the interaction of GPCRs
with all G-protein subtypes is becoming more complete, the
dynamic processes that underlie the mechanisms by which
agonist-activated GPCRs interact with intracellular arrestins
is still fragmentary. Arrestin is an important intracellular
interaction partner of GPCRs that desensitizes G-protein-
mediated signaling and creates the signal for receptor
internalization.[3] Until recently, structural data was only
available for the complex of bovine (rhod)opsin with arrest-
in.[4, 5] Now, cryo-EM structures of the neurotensin receptor
1,[6] the b1 adrenoceptor,
[7] and the muscarinic M2 receptor[8]
in complex with b-arrestin 1 (also known as arrestin-2) have
become available.
To fully understand the biological function of GPCRs in
interaction with intracellular effectors, monitoring the con-
formational dynamics of specific sites by biophysical spec-
troscopy is most promising. Magnetic resonance methods
such as EPR and NMR have been of key importance in this
regard.[2, 9] Recently, DEER spectroscopy was used to map
conformational changes of angiotensin II receptor using spin
labels.[10] This study revealed that different ligands induce
diverse conformational signatures. In NMR spectroscopy,
either native probes such as the methyl group of methio-
nine[11,12] and the indole ring of native or artificially intro-
duced tryptophan (Trp) residues[13–15] or artificial fluorine
labels attached to free cysteines[16, 17] have been used to
describe the individual structural states of GPCRs during
activation. The detected NMR chemical shift of a given site
depends on the local chemical environment and protein
structure, thus, alterations in NMR peak position indicate
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structural modifications in the receptor in response to agonist
or G-protein binding.[18] Various NMR studies conducted in
the absence and presence of ligands as well as intracellular
binding partners such as G-proteins, nano- or antibodies
showed that GPCRs assume distinct conformations charac-
teristic for the individual states.[18] While agonist binding
appears to destabilize the inactive state, it is not sufficient to
stabilize the fully active receptor conformation.[12]
The current model of GPCR activation describes a num-
ber of well conserved residues that are crucial for the
structural rearrangements of the protein upon activation,
referred to as molecular switches.[19] Using spectroscopic
tools, the structural rearrangements of these residues can be
studied in detail to understand the activation mechanisms of
a GPCR for which the crystal structures of all substrates are
not available. Here, we target the neuropeptide Y2 receptor
(Y2R) and describe the conformational responses of specific
sites of the molecule to ligand- and arrestin-3 (also known as
b-arrestin 2) binding. Y2R is involved in the control of food
intake and memory retention, mood disorders and epilepsy.[20]
Its natural ligand is the 36 residue hormone neuropeptide Y
(NPY) that forms an amphipathic C-terminal a-helix.[21]
Upon binding to Y1R[22] and Y2R,[23] unwinding of the C-
terminal residues was detected allowing the agonist to reach
deep into the binding pocket. On the intracellular side, Y2R
couples to the inhibitory family of G-proteins (Gi/o)
[24] and has
also been shown to recruit arrestin-3.[25] Furthermore, Y2R in
membranes was characterized as a highly mobile molecule in
solid-state NMR experiments but without site-resolution.[26,27]
To provide a detailed site-specific analysis of the dynamic
properties of Y2R in the various functional states, native Trp
residues represent valuable probes. In Y2R, there are only six
native Trp, which significantly reduces the spectral complexity
for NMR investigations. Using isotopically labeled native Trp
residues as probes allows to (i) study the structure and
dynamics of the Ca backbone with site resolution in (ii) a
DMPC phospholipid membrane representing a very natural
environment of GPCRs. The six Trp residues in Y2R are fairly
equally distributed over the structure of Y2R (Figure 1) with
two Trp in the extracellular loops (Trp11623.50, Trp2075.26, the
superscript refers to the Ballesteros-Weinstein nomencla-
ture[28]), one in the center of TM4 (Trp1734.50), the “toggle
switch” Trp2816.48 pointing into the ligand binding pocket, and
two Trp on the intracellular side (Trp2435.62 and Trp3277.55).
Thus, the six native Trp residues yield information from
several key motifs of the receptor. By integration of cell-free
(CF) protein expression, dynamic nuclear polarization en-
hancement (DNP) and conventional NMR methods, specif-
ically 13C-labeled Y2R was prepared and the individual
conformational changes of the different structural motifs of
the Y2R in response to ligand and arrestin-3 binding were
analyzed.
Figure 1. Sequence and structural architecture of Y2R and assignment of the 13Ca-Trp signals of Y2R in DMPC membranes. A) Snake plot showing
the Y2R construct used in this study with artificial amino acid insertions at the N- and C-termini (gray). Cysteines not involved in disulfide bond
formation were replaced by Ala or Ser (dark gray). The six 13C labeled Trp are colored. B) Structural model of Y2R[23] with the Trp residues
represented as stick models. C) Ca/Cb region of a 13C-13C DARR NMR spectrum of Y2R recorded at a temperature of @30 8C with the assignment
to the specific residues. D) Ca region of the DNP NCOCX spectra used for signal assignment. NMR spectra were recorded using DNP for signal
enhancement at a temperature of @164 8C. The labeling scheme for the sample preparation indicating the 13C-labeled Trp and its 15N-labeled
successor amino acid is given. See also Supplementary Figure S2.
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Results and Discussion
Cell-Free Expression, Reconstitution, and Pharmacology of Y2R
Y2R used in this study was prepared by CF expression in
the precipitated form. For better expression yields, the
construct contained short N- and C-terminal amino acid
insertions along with a His tag for purification (Figure 1). Six
Cys residues not involved in disulfide bond formation were
replaced by Ala or Ser to eliminate receptor aggregation
during refolding.[29] The term “Y2R” below refers to this
construct. CF expression, purification and reconstitution of
Y2R are detailed in the experimental section (Figure S1).
Briefly, after CF expression, precipitated Y2R was solubilized
by SDS in the presence of DTT. Y2R was purified and the
SDS concentration was reduced in the presence of a redox
shuffling system to form the native disulfide bridge. Y2R was
reconstituted in preformed DMPC/DHPC bicelles.[30] By
removal of DHPC, planar membranes were formed with
a residual DHPC content of less than 5 to 10%. The ligand
binding capacity of the reconstituted receptor was shown by
a fluorescence polarization assay[31] and the KD value for NPY
binding was determined to be & 35 nM (Figure S1). To
prepare Y2R in different functional states, NPY as well as
the phosphorylation-independent arrestin-3-3A variant[32]
were added. Binding of arrestin-3-3A was confirmed by
a pull-down assay (Figure S1).
NMR Investigation of the Trp Sites of Y2R
For the NMR experiments, all Trp residues were 13C-
labeled by adding U-13C-Trp to the CF reaction mix. Using
dipolar assisted rotational resonance (DARR) NMR spec-
troscopy (10 ms mixing time) at @30 8C, all one bond
correlations were observed. Most characteristic is the Ca/Cb
region of the DARR NMR spectrum with six relatively well
resolved crosspeaks at chemical shifts between & 53 and
59 ppm for the 13Ca and & 24 to 31 ppm for the 13Cb sites
(Figure 1C). To assign these signals, a mutagenesis approach
as described in the literature[13, 14, 33] was first considered. Y2R
mutants were prepared each with one Trp replaced by Phe or
Thr. But no full unambiguous assignment could be extracted
from these experiments due to unpredictable chemical shift
changes. In alternative experiments, the 13C NMR signals
from each Trp were assigned through correlations to the
successive 15N-labeled residue by NCOCX correlation spec-
tra.[34] To this end, six 13C-Trp/15N-X-labeled Y2R variants
were prepared using U-13C-Trp and 15N-labeling of the
successor residue type (X). Fortunately, the Y2R sequence
contains six unique amino acids following Trp allowing for
unambiguous assignment of the following pairs: 13C-
Trp11623.50/15N-Lys11723.51, 13C-Trp1734.50/ 15N-Gly1744.51, 13C-
Trp2075.26/15N-Pro2085.27, 13C-Trp2435.62/15N-Ser2445.63, 13C-
Trp2816.48/15N-Leu2826.49, and 13C-Trp3277.55/15N-Met3287.56.
To increase the sensitivity, NMR experiments were carried
out using dynamic nuclear polarization (DNP)[35] yielding
enhancement factors between & 40 and 70 (Figure S2). The
six 1D NCOCX spectra were referenced internally using the
signals of glycerol and superimposed providing the unique
13Ca chemical shifts for all Trp residues. The assigned Ca/Cb
region of the 13C-13C DARR NMR spectra is shown in
Figure 1D. The DNP NMR experiments had to be performed
at @164 8C in the presence of the biradicyl AmuPOL (Fig-
ure 1D). In spite of the increased NMR linewidths under
these conditions, the DNP NMR spectra provided 13C chem-
ical shift information for each Trp with the exception of
Trp3277.55 and Trp1734.50, which were ambiguous. The NMR
assignment of Trp2816.48 and Trp3277.55 were confirmed by
W281T and W327F mutants studied at @30 8C (see Fig-
ure S2A,B). The chemical shifts of the Trp residues deter-
mined at low temperature under DNP conditions were
transferred to the @30 8C studies assuming that the sequence
of shifts from highest to lowest field did not change. As the
Y2R does not undergo melting or other large structural
changes in this temperature range, no significant chemical
shift changes are expected.
Native Trp Residues Report the Conformational Dynamics of Y2R
To record conformational changes of Y2R during activa-
tion, the receptor was prepared in three functional states:
(i) the apo state, (ii) the NPY-bound state (full agonist bound
state), and (iii) as a ternary complex with NPY and arrestin-3.
Superposition of the corresponding 13C NMR spectra re-
vealed characteristic chemical shift changes that can be
assigned to dynamic conformational changes of Y2R upon
activation (Figure 2A).
In the apo state, the NMR signals of Trp11623.50, Trp2435.62,
and Trp2816.48 are relatively sharp and well separated
indicating a single conformation for each of these sites.
Trp1734.50, Trp2075.26, and Trp3277.55 display two NMR signals
referring to two different conformations. Binding of NPY
leads to distinct spectral changes and peak splitting indicative
of multiple conformations especially for residues Trp3277.55,
Trp2075.26, and possibly Trp2816.48. The differences in chemical
shift between resolved NMR signals indicate that the
conformations are in slow exchange (the lower correlation
time limit is t& 1 ms). The NMR signal of Trp1734.50 shows
a moderate upfield shift upon agonist binding, whereas the
signals of Trp2435.62 and Trp11623.50 do not change.
The arrestin-3 bound conformation of the receptor is
characterized by one single and sharp NMR signal for four
Trp residues suggesting that the receptor has reached a more
stable state with lower conformational flexibility. However,
for Trp3277.55, two weak signals indicative of lowly populated
conformations and for Trp2075.26 a weak peak shoulder
indicates residual conformational diversity. These two resi-
dues also show weaker signal intensity suggesting higher
dynamics as cross-polarization is less efficient. Trp3277.55
provides an NMR signal shifted downfield by the largest
amount from both the apo and the NPY-bound states. The
NMR signal of Trp2075.26 was shifted slightly upfield as
compared to the apo state and found in between the two
signals observed for the NPY-bound state. The Trp1734.50 peak
was shifted slightly upfield from the apo state at a similar
position as in the NPY-bound state. The NMR signals of
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Trp2435.62 and Trp11623.50 did not change position relative to
both the apo and the NPY-bound states.
Backbone Motional Amplitude of the Trp Residues in Y2R
To further characterize the conformational dynamics of
the Y2R on a fast timescale, molecular order parameter
describing the motional amplitude of a bond vector were
determined. We used DipShift experiments[36] at 5 8C to
measure the motions of the backbone 1Ha-13Ca bond vectors
of all Trp in Y2R (Figure S3). Order parameters are sensitive
to fluctuations with correlation times t< 40 ms. Order param-
eters (S, with S = 1 representing completely rigid, and S = 0
isotropically mobile segments) measured in each conforma-
tional state are shown in Figure 3.
Trp3277.55 shows the lowest order parameter of 0.71. The
other five Trp residues showed order parameters between
0.82 and 0.85. Addition of NPY and arrestin-3 did not
significantly alter these values based on the errors from at
least two independent preparations. For comparison, the
order parameter of all backbone sites including the loops and
termini of Y2R was previously determined to be 0.69.[26] The
Trp residues measured here with site-resolution are localized
in either stable secondary structure motifs, loop structures
(Trp2075.26), or stabilized by the disulfide bridge (Trp11623.50)
explaining their somewhat higher values. Order parameters of
0.70 to 0.80 correspond to motional amplitudes in the
backbone of & 358 to 308.
Trp Residues Report the Conformational Dynamics of Y2R in
Membranes
Many studies have shown that GPCRs exist in several
conformations and their biological function is not simply
described as an on/off equilibrium of the inactive and active
conformations, but follows a complex pattern of highly
dynamic structural changes between several substrates.[17,37]
These dynamic conformational transitions during activation
and interaction with intracellular effectors can only be studied
in atomistic detail using spectroscopy.[18,38] The conforma-
tional ensemble of a GPCR in the lipid bilayer is distinctly
different from that in detergent micelles[37] necessitating the
Figure 2. Conformational changes of the native Trp residues of Y2R as observed by 13C NMR. A) Ca/Cb region of 13C-13C DARR NMR spectrum of
13C-Trp-labeled Y2R in DMPC membranes at @30 8C in different functional states: the apo state (top row), the NPY-bound state (middle row), and
the NPY- and arrestin-3 bound state (bottom row). B)–E) Structural details of the Y2R model[23] highlighting the interactions of the Trp residues.
B) The sidechains of Trp2435.62 and Trp3277.55 localized on the intracellular side face the membrane. C) Residue Trp11623.50 forms a “cysteine lock”
as the indole ring is stacked against the conserved disulfide bridge. D) Y2R is shown in the NPY-bound state indicating the interaction of the
toggle switch residue Trp2816.48 with the C-terminal residue Tyr36 of NPY (black). E) Same model as in D) displaying the conformation of
Trp2075.26 in the apo and the NPY-bound states indicating the putative conformational changes between these two states.[23]
Figure 3. Motional order parameters of the 1Ha-13Ca bond vectors of
the six Trp residues in Y2R in the apo form, with NPY-bound, and with
NPY and arrestin-3. Experiments were carried out in DMPC mem-
branes at 5 8C.
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investigation in planar membranes. With the current solid-
state NMR data, determined in membranes, we describe
molecular details of the structural dynamics of Y2R upon
binding to its full agonist NPY and in interaction with
arrestin-3-3A. Currently, there is no crystal structure avail-
able for Y2R in any conformational state. In our approach,
Y2R produced in CF synthesis with 13C-labeled Trp residues
was reconstituted into DMPC membranes allowing to study
its activation in a native environment. The probes for the
analysis were the Trp backbone atoms, which directly report
conformational alterations that are not masked by sidechain
or probe rotameric states or any artificial labels.
Trp residues rigidify the protein backbone. The indole ring
with its large surface is frequently involved in hydrogen
bonds, p stacking, cation-p, and van der Waals interactions.
These properties render Trp residues relatively rigid sites in
proteins undergoing only small librations.[39] Three of the six
Trp of Y2R do not report significant structural alteration
when the molecule goes through the activation cycle. These
are localized in the ECL1 (Trp11623.50), TM4 (Trp1734.50), and
at the transition region from TM5 to ICL3 (Trp2435.62) and can
be considered as located in well-preserved structural motifs.
The other three Trp reflect the dynamic conformational
equilibrium reported by pronounced chemical shift changes
indicative of structural alterations.
The Functional and Structural Roles of Trp in Y2R
The NMR results reveal key functions of the Trp residues
located in different regions of Y2R. Trp2075.26, Trp2816.48, and
Trp3277.55 are subject to conformational flexibility. For these
residues, multiple chemical shifts indicative of different
receptor conformations were observed in the apo state, which
are in slow exchange on the millisecond timescale. Agonist
binding is not sufficient to stabilize one active conformation
of the molecule. The most well-known site is Trp6.48 described
as the “toggle switch” of activation. In all GPCRs investigated
so far, TM6 undergoes a large conformational change upon
agonist binding representing the most universal feature of
these molecules.[19,37, 40] Trp2816.48 is part of the CWxP motif,
identified as a SWLP sequence in Y2R and highly conserved
in class A receptors. It is located at the bottom of the ligand-
binding pocket in close proximity to the C-terminal residue
Tyr36 of the agonist (Figure 2D).[23] Mutagenesis experiments
showed that Trp2816.48 does not significantly contribute to
ligand affinity but is required for receptor activation and
downstream signaling. Mutagenesis to Thr, His or Tyr
strongly reduced the efficacy to activate the G-protein
pathway and to recruit b-arrestin to the receptor.[41] The
Trp2816.48 NMR signal most significantly shifts by > 1 ppm
upfield upon addition of NPY. This is the most prominent
chemical shift change of any of the Trp residues upon ligand
binding indicating the importance of Trp2816.48 in activation.
The crystal structure of the A2A receptor revealed that agonist
binding causes a pronounced structural alteration at the
position of Trp6.48, prompting TM6 to tilt and rotate.[42] The
importance of Trp6.48 in TM6 of rhodopsin has also been
described.[15] It is reasonable to hypothesize that TM6 in Y2R
undergoes similar conformational changes resulting in the
observed chemical shift changes of Trp2816.48. No further
conformational changes are observed in the arrestin-3 bound
state of Y2R confirming that agonist binding causes the
required structural alteration of TM6 for interaction of Y2R
with arrestin.
Prominent structural diversity was observed for Trp3277.55,
located on the intracellular side at the TM7/H8 region, known
to undergo large conformational changes in GPCRs upon
activation.[43] The position of Trp3277.55 is usually occupied by
a Phe or another hydrophobic residue in other GPCRs.
Trp3277.55 is located in the flanking region of TM7, in the apo
state most likely oriented towards the membrane and in close
proximity to the conserved NPxxY7.53 motif. The structure of
the (rhod)opsin/arrestin complex indicate that residues
Asn7.57, Lys7.58, and Gln7.59 are localized in close proximity to
arrestin[5] suggesting that Trp3277.55 is highly relevant to report
conformational changes upon arrestin binding. Also, in the
structure of the neurotensin receptor/arrestin complex,[6]
residues Val7.56, Ser7.57 and Ala7.58 interact with the arrestin
fingerloop corroborating that Trp3277.55 responds sensitively
to arrestin binding. Comparison of inactive and active states
of class A GPCRs shows that the tip of TM7 undergoes an
inward movement upon activation.[44] Thereby, the sidechain
of residue 7.55 orients parallel to the backbone of helix 8,
most often in a stacking interaction with the sidechain of Lys/
Arg8.51. This results in a more fixed conformation upon
binding of the intracellular binding partner. However, our
data show residual conformational flexibility and appreciable
dynamics of Trp3277.55 in the arrestin-3-3A bound state.
Our results suggest an allosteric coupling of Trp3277.55 as
described for Trp on the intracellular surface of the A2A
adenosine receptor.[14] In the apo state of Y2R, a relatively
broad NMR signal was detected for Trp3277.55 indicating
multiple conformations. In the NPY bound state, two clearly
separated signals (at & 59.6 ppm and & 58.8 ppm) of approx-
imately equal intensity were observed reflecting two distinct
conformations. After formation of the ternary complex with
arrestin-3, some conformational as well as the dynamic
flexibility remains, however, there is one preferred confor-
mation that is most highly populated. But lower signal
intensity indicates a relatively mobile state even at @30 8C.
Measurements of the motional amplitude of the Ca-Ha bond
vector of Trp3277.55 on a fast time scale indicated that it shows
the largest amplitude of motion (& 428, Figure 3). The side
chain of Tyr7.53 of the NPxxY motif is repositioned upon
activation of GPCRs[2] and an inward movement of Tyr7.53 at
the intracellular end of TM7 has been observed in the
neurotensin receptor.[45] Our results suggest that Trp3277.55 of
Y2R may also undergo such rearrangement.
The third Trp residue for which a conformational equi-
librium is observed is Trp2075.26, located in the ECL2 of Y2R.
A broad NMR peak in the apo state suggests Trp2075.26 to be
structurally flexible. Hydrophobic contacts with the agonist
are believed to constrain NPY at an angle of approximately
458 relative to the membrane normal.[23] Thr2045.23 and
Glu2055.24 in close proximity to Trp2075.26 significantly con-
tribute to NPY binding energy.[23] Thus, it was expected that
Trp2075.26 is influenced by the agonist. In the apo state,
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Trp2075.26 points towards the inside of Y2R. It is involved in
interactions with TM5, TM6 and the antiparallel strand of the
extracellular b-sheet. Upon NPY binding, Trp2075.26 shows
two NMR signals suggesting two different conformations. In
the NPY bound state, Trp2075.26 is sandwiched between TM4
and TM5 at least in one conformation (Figure 2E). The
conformational flexibility of Trp2075.26 in the agonist bound
state reflected in the two peaks in the DARR NMR spectrum
was significantly abrogated upon arrestin-3 binding showing
one dominating NMR signal of lower intensity with residual
molecular dynamics.
Little structural dynamics was found for Trp1734.50.
Although highly conserved (94 %) within the rhodopsin-like
GPCR family, only a slight upfield shift of the NMR signal of
Trp1734.50 was detected upon NPY and arrestin-3 binding.
Trp2435.62 is located at the end of TM5 pointing towards
the membrane.[23] No functional importance has been as-
signed to this site. It is not conserved within class A GPCRs or
the NPY receptor family. While it is membrane exposed,
there is no indication for conformational flexibility. In the
model of Y2R,[23] Trp2435.62 is in a one-helix-turn distance to
Tyr2395.58 which shows 75 % conservation in class A GPCRs.
Upon activation, Tyr5.58 forms hydrogen bonds to Tyr7.53 of the
NPxxY7.53 motif as well as to Arg3.50 of the DRY/ERY motif,
considered as “water lock”.[44] Comparison of inactive and
active states of GPCR structures shows that despite the
formation of new interactions, the relative positions of Tyr5.58
and residue 5.62 do not change upon binding of the intra-
cellular binding partner explaining the lack of any response of
Trp2435.62 to arrestin-3 binding.
Finally, an interesting role in the architecture of Y2R is
found for Trp11623.50, located in the conserved WxxG motif of
ECL1. It is expected to pack with its indole ring against the
conserved disulfide bridge.[39] Examining the available crystal
structures, a Cys lock motif is observed in many class A
GPCRs and appears to stabilize the conformation. In some
cases even two or three Trp are in the vicinity of the disulfide
bridge and might stabilize the conformation of this region
(e.g. in the histamine H1, muscarinic and serotonin recep-
tors). Furthermore, comparison of the inactive and active
states of rhodopsin and b2-adrenergic receptor shows that this
motif is independent of the activation state. This was also
reflected in the 13C NMR spectra, where the peak of
Trp11623.50 showed no chemical shift alterations.
In contrast to the dynamic transitions between the
individual conformations of the Y2R during the activation
cycle seen as exchange broadening in 13C NMR spectra
reflecting conformational transitions, explicit measurements
of the amplitudes of the fast fluctuations of the Trp residues
did not produce significant differences (Figure 3). This
suggests that the fast thermal fluctuations reflecting the
packing of the receptor interior and its interaction with the
lipid molecules is not influenced by the dynamic transitions
between the conformational states on the lower microsecond
and sub-microsecond time scale as probed in the DipShift
experiment. Thus, DipShift probes the conformational flex-
ibility in the individual wells of a given state, while the
exchange-broadening of the NMR signals reports the biolog-
ically relevant conformational transitions.
Conclusion
We describe the conformational states of Y2R during
activation by analyzing NMR chemical shift information from
six natural Trp residues. Trp have been used as probes to study
the dynamic conformational alterations of GPCRs be-
fore.[13, 14, 33] However, instead of the protein backbone, usually
the NMR signals of the indole ring were exploited. Analyzing
the receptor backbone sites provides the most direct approach
to observing the structural response of the molecule to agonist
and intracellular effector binding.[15] Using solid-state NMR
spectroscopy, GPCRs are studied in a relatively native bilayer
environment.[46] As in other class A GPCRs, the activation of
Y2R is mediated by a series of dynamic conformational
changes which are reported here by the native Trp residues.
Our results on the structural dynamics of the Y2R are
summarized in Figure 4. The measurements revealed a con-
formational equilibrium of Y2R in the apo and agonist bound
states. This flexibility is reduced upon arrestin binding which
largely stabilizes one predominant conformation that is
different from the apo and agonist bound states. However,
some residual conformational flexibility and molecular dy-
namics of Y2R in that state remains. Out of the well-described
molecular switches triggered upon GPCR activation, the
toggle switch residue Trp2816.48 showed a pronounced re-
sponse to agonist and arrestin-3 binding in agreement with an
outward movement of TM6 upon activation. Furthermore,
residues Trp2075.26 and Trp3277.55 at the TM7/H8 boundary
close to the NPxxY motif report further structural alterations
during activation. For the opsin/arrestin complex,[5] a similar
structural architecture as in the b2-adrenergic receptor/Gs
complex has been identified[47] involving the interaction of the
finger loop of arrestin with the NPxxY motif also observed in
Figure 4. Summary of the structural dynamics of Y2R visualizing the
conformational equilibria of the Y2R in the apo state (left), in the NPY-
bound state (middle) and in complex with NPY as well as arrestin-3-3A
(right). Trp residues with low, intermediate, and high conformational
flexibility are highlighted by blue, yellow, and red circles, respectively.
The structures on the left side and in the middle refer to the published
structural models,[23] the complex shown on the right represents just
a visualization of arrestin binding for illustration.
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Y2R. In the GPCR-arrestin complexes, a multimodal inter-
action network that also includes arrestin interactions with
the membrane has been identified.[6–8] The intriguing mem-
brane contribution to GPCR/arrestin complex formation
specifically calls for investigating the GPCR/arrestin inter-
action in membrane environment as carried out in the current
study. Finally, Trp11623.50-Cys lock formation was identified
for Y2R. The combination of cell-free labeling, investigation
of the conformational states of the backbone sites by solid-
state NMR in membranes, and the investigation of the
interaction of GPCRs with specific lipids represents an
attractive option to gain biological insight into the function
of GPCRs, for which no crystal structures are available.
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